Market News & Trends
Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push
Eli Lilly said it will buy three vaccine developers in deals worth up to $3.8 billion in combined value, signaling its push into infectious disease…
MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient centric solutions for cardiometabolic and orphan lung diseases, today…
Recipharm boosts BFS capacity with strategic manufacturing investment
Recipharm, a global contract development and manufacturing organization (CDMO), today announced a multi-million investment in a new Blow-Fill-Seal (BFS) manufacturing line, expanding capacity to support…
Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute
TOKYO – Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute. This modality enables…
Cereno Scientific Doses First Volunteer in CS014 PK-bridging Study
Cereno Scientific, an innovative biotech pioneering treatment to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the first…
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Soligenix, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that…
Orexo announces positive outcome from an in-vivo study of OX390
Uppsala, Sweden – Orexo AB, today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX…
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, today announces that it has…
FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison
Fujifilm Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs), today celebrated the opening of its new headquarters and…
VoxCell BioInnovation & adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform
VoxCell BioInnovation Inc. (“VoxCell”), a developer of bioprinted vascularized human tissue models for preclinical drug development, and adMare BioInnovations (“adMare”), Canada’s life sciences company creation…
Vetter Starts Construction of a New Production Site in Germany
Vetter, a leading Contract Development and Manufacturing Organization (CDMO), is celebrating the start of construction on its new site in Saarlouis with a traditional groundbreaking…
OrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development & Manufacturing Organization
OrganaBio, LLC has acquired substantially all of the operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing…
Terumo Blood & Cell Technologies & Steminent Collaborate to Advance MSC Late-Stage Clinical Manufacturing
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions, and Steminent Biotherapeutics have entered into a strategic collaboration to accelerate late-stage…
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Zenas BioPharma, Inc. recently announced that the first subject has been dosed in the Phase 1 trial of ZB021, a novel potentially best-in-class oral IL-17AA/AF…
Enterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With Novel Inhaled ENaC Blocker ETD001
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases,…
Brainomix & Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced an expansion of its partnership with Boehringer Ingelheim,…
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the successful completion…
Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases,…
Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support of SiranBio’s Dual-Target siRNA Program
Hongene Biotech Corporation recently announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end…
Bracco Launches BubbleGen Early Access Program for Microbubble-Based Cell Selection & Activation at ISCT
Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program to enable cell therapy developers to evaluate the…
